The measurement layer
your
outcomes work depends on.
Sensor‑verified, quantity‑level dose data — across solid‑oral, topical, and liquid forms. The input your evidence, protocol, and program decisions rest on.
Pharma · Medical Affairs & HEOR
Phase 4 and post‑marketing evidence
demands measurement‑grade data.
Real-world adherence data generated from proxy-event sensors carries an interpretive footnote in every analysis. Quantity-level data does not. MyAide produces a measurement record that can be cleanly stratified, modeled, and defended in HEOR analyses, registries, post-authorization safety studies, and label-expansion evidence packages.
Trial-grade adherence, zero site burden.
Bluetooth and WiFi-connected hardware, no patient app required, and a sponsor dashboard that delivers the data directly. Validated to 100% pill-count agreement and 99% time-of-administration accuracy — defensible in protocol-deviation review and primary-endpoint sensitivity analyses, with CDISC/SDTM-compliant output that integrates into existing trial data infrastructure.
Adherence data your pharmacists
can act on the same day.
MyAide flags partial doses, missed doses, late doses, and double doses at the patient level — not month-end claims aggregates. Clinical pharmacists can intervene during the actual gap, not after a refill has lapsed.
The compliance signal your outcomes model is missing
RPM platforms monitor vitals. Adherence coaching motivates behavior. Neither answers the question that drives the residual variation in every outcomes dataset — did the patient actually take the medication — and MyAide closes that gap with a verified compliance variable that integrates beneath your existing dashboard. The more complex the regimen, the more the signal matters.
The validated foundation, in the indication that built it
RPM platforms monitor vitals. Adherence coaching motivates behavior. Neither answers the question that drives the residual variation in every outcomes dataset — did the patient actually take the medication — and MyAide closes that gap with a verified compliance variable that integrates beneath your existing dashboard. The more complex the regimen, the more the signal matters.
Dr. Steven Feldman, Wake Forest — among the world’s most-cited researchers in dermatology and psoriasis adherence.
Trial-grade adherence, zero site burden.
Bluetooth and WiFi-connected hardware, no patient app required, and a sponsor dashboard that delivers the data directly. Validated to 100% pill-count agreement and 99% time-of-administration accuracy — defensible in protocol-deviation review and primary-endpoint sensitivity analyses, with CDISC/SDTM-compliant output that integrates into existing trial data infrastructure.
Act on adherence the same day.
MyAide flags partial doses, missed doses, late doses, and double doses at the patient level — not month-end claims aggregates. Clinical pharmacists can intervene during the actual gap, not after a refill has lapsed.
The compliance signal your
outcomes model is missing.
RPM platforms monitor vitals. Adherence coaching motivates behavior. Neither answers the question that drives the residual variation in every outcomes dataset — did the patient actually take the medication — and MyAide closes that gap with a verified compliance variable that integrates beneath your existing dashboard. The more complex the regimen, the more the signal matters.
The validated foundation
in the indication that built it
.
Sensal’s measurement architecture was validated in dermatology — the only peer-reviewed gravimetric adherence dataset in the field, published in JAAD and the Journal of Dermatological Treatment. Smart Cap covers tube-based topicals; Smart Dock covers oral derm agents. Together they produce the verified application and ingestion record that refill data and patient diaries cannot.